Apollo is obviously the most important near-term event for Alnylam, but the rest of the company's pipeline is progressing well. In addition to the aforementioned phase 3 hemophilia program for fitusiran, the company will start two more phase 3 programs this year: The first is an investigation of givosiran for a rare disease called acute hepatic porphyria; the second is partner The Medicines Company 's ( MDCO ) planned phase 3 program for the jointly developed cholesterol drug inclisiran.